ScreenerHero

VKTX Viking Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · vikingtherapeutics.com
28.54USD+0.56%Mkt Cap: 3.63B $P/E: —

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue an…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.63B USD
Enterprise Value2.81B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-359.64M USD
Revenue/Share—
Last Price28.54 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees65
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.45
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B8.11
EPS (TTM)-4.53
EPS (Forward)-4.40
52W Range
24.7820% of range43.15
52W High43.15 USD
52W Low24.78 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-56.28%
ROA-50.25%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-278.69M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-6.36%
Net Debt-497.58M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio4.72
Quick Ratio4.58
Book Value/Sh3.50 USD
Cash/Share4.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)94.82 USD
Upside (mean)+232.2%
Target Range38.00 USD – 125.00 USD
38.00+232.2% to mean125.00
# Analysts19
Ownership
Shares Out.127.17M
Float113.73M
Insiders2.84%
Institutions60.61%
Short Interest
Short Ratio12.3d
Short % Float20.19%
Short % Out.19.12%
Shares Short22.58M
Short (prev mo.)22.29M
Technical
SMA 5033.24 (-14.1%)
SMA 20033.13 (-13.9%)
Beta0.65
S&P 52W Chg16.45%
Avg Vol (30d)6.21M
Avg Vol (10d)14.23M
Technical Indicators
RSI (14)39.4
MACD-1.2328
MACD Signal-0.5681
MACD Hist.-0.6648
BB Upper40.15 USD
BB Middle32.74 USD
BB Lower25.32 USD
BB Width45.31%
ATR (14)2.400 USD
Vol Ratio (20d)0.65x